TheraRadar
← Back
Data updated: Jun 28, 2026

UNICHEM

Generics

UNICHEM is a generic drug manufacturer focused on Cardiovascular, Neurology, Gastroenterology.

2006
Since
67
Drugs
-
Trials
1
New Drugs (2yr)
Modality:
1 Small Molecules

UNICHEM's Key Drugs

UNICHEM's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

UNICHEM's Therapeutic Areas

UNICHEM's approved drugs and pipeline span 4 therapeutic areas, led by Cardiovascular and Neurology, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Cardiovascular 57%
12 drugs
Neurology 29%
6 drugs
Gastroenterology 10%
2 drugs
Immunology 5%
1 drugs

UNICHEM's Top Competitors

UNICHEM's closest competitors by therapeutic-area and drug-target overlap include WARNER CHILCOTT, Bristol-Myers Squibb, and BAUSCH. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

UNICHEM Pipeline Snapshot

Active clinical trials for UNICHEM across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • Top drug revenue breakdown
  • Drug-level revenue analysis

Trial Catalysts

  • Cardiovascular pipeline focus
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling